Preeclampsia is a systemic hypertensive condition marked by elevated blood pressures and proteinuria that is unique to pregnancy. Preeclampsia increases the risk of fetal growth restriction, preterm birth, Cesarean delivery, long-term maternal cardiovascular disease, and is a leading cause of maternal and fetal morbidity and mortality.
1 In a recent meta-analysis of 16 clinical trials, low-dose aspirin (LDA) reduced the risk of preeclampsia by 15%,
1-3 especially when it was started before 16 weeks’ gestation. The United States Preventive Services Task Force (USPSTF) recommends LDA (81 mg/d) for the prevention of preeclampsia in individuals with a preeclampsia risk of 8% or higher, based on the presence of certain known risk factors.
4